Beam Therapeutics (BEAM) Change in Accured Expenses (2019 - 2026)

Beam Therapeutics (BEAM) has reported Change in Accured Expenses for 8 consecutive years, with -$16.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 11.92% year-over-year to -$16.3 million; the TTM figure through Mar 2026 stood at $9.9 million (up 119.06% YoY), while the FY2025 annual figure was $7.7 million, up 113.32% from the prior year.
• Change in Accured Expenses declined to -$16.3 million in Q1 2026 per BEAM's latest filing, from $14.3 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $70.4 million in Q4 2023 and bottomed at -$24.3 million in Q1 2024.
• Historically, Change in Accured Expenses has averaged $38411.8 across 5 years, with a median of -$266000.0 in 2023.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses soared 733.84% — and 2024, when it sank 7225.56%.
• Beam Therapeutics' Change in Accured Expenses stood at $8.4 million in 2022, then jumped by 733.84% to $70.4 million in 2023, then sank by 105.79% to -$4.1 million in 2024, then surged by 450.87% to $14.3 million in 2025, then plunged by 213.71% to -$16.3 million in 2026.
• Business Quant data shows BEAM's Change in Accured Expenses at -$16.3 million in Q1 2026, $14.3 million in Q4 2025, and $2.0 million in Q3 2025.